Highly Optimised Autologous T Cell Therapy Following Cancer Vaccination
Time: 12:00 pm
day: Day Two
Details:
- Reviewing detailed characterisation of the immune response in cancer patients to neo Ag and TAA vaccination
- Pioneering the use of immune screening to successfully harvest vaccine-Ag-specific T cells as the basis for T cell therapy
- Creating highly optimised GMP in vitro expansion of vaccine-Ag specific T-cells for therapy
